Vizgen develops and commercializes spatial multi-omics technologies that allow scientists to map RNA and protein expression within tissue samples at single-cell resolution. Its flagship MERFISH 2.0 chemistry powers the MERSCOPE Platform, enabling high-throughput, in-situ spatial transcriptomics. Complementing this, the company offers InSituPlex protein assays and the AI-driven STARVUE spatial image-analysis software, creating an integrated workflow for comprehensive tissue profiling. These offerings are intended for research use only and are applied to studying complex diseases such as neurodegenerative disorders and cancer. Vizgen was co-founded by academics Xiaowei Zhuang, David Walt, and Jeffrey Moffitt and is led by CEO Rob Carson. The company operates R&D and lab-services facilities in nearby Cambridge, Massachusetts. With fresh capital in hand, management aims to expand global customer support and scale manufacturing of its platforms. No revenue or user metrics were disclosed in the article.

Total raised

$184M

Funding rounds

4

Latest round

Equity

Latest activity

Jan 2026